


Preexcitace

J. Janoušek

Children's Heart Centre, University Hospital Motol,
Prague, Czech Republic



Anatomy of accessory atrioventricular pathways



Courtesy Paul T, Göttingen, Germany

Accessory Atrioventricular Myocardial Connections in the Developing Human Heart: Relevance for Perinatal Supraventricular Tachycardias


Nathan D. Hahurij, Adriana C. Gittenberger-De Groot, Denise P. Kolditz, Regina Bökenkamp,
Martin J. Schalij, Robert E. Poelmann and Nico A. Blom

Circulation. 2008;117:2850-2858; originally published online May 27, 2008;

N = 45 human embryonic, fetal and neonatal hearts

Immunohistochemical examination of accessory myocardial AV connections

- 4 - 6 WOG A and V myocardium continuous at the primitive AV canal
- 6 - 10 WOG numerous accessory myocardial AV connections
 - left (45%), right (35%), septal (20%)
- 10 - 20 WOG accessory AV connections decreased in number
- >20 WOG no accessory myocardial AV connections observed



Conclusions from fetal studies


- AV ring isolation is a gradual process
 - May continue postnatally



- AV reentrant tachycardias often spontaneously obliterate before 1 year of age

Natural history in childhood

AGE AT SVT "ONSET" (POOLED DATA)



- WPW syndrome (prevalence 0.15-0.3 %)
 - Presentation with SVT <2 mo of age (Perry JC et al, JACC 1990)
 - 93 % disappear by 1 year
 - 31 % reappear at average age of 8 yrs
 - If symptomatic at >5 yrs, 78 % long-term persistence



Population-based studies

- Prevalence of supraventricular arrhythmia
2.25/1000 persons
- Annual incidence in children <19 years of age
13/100 000 persons
 - In 10 583 children (www.paces.org)
undergoing EPS/RFA
AVRT (accessory pathways) in 67%



Terminology


- Wolff-Parkinson-White Syndrome
 - Preexcitation in sinus rhythm
 - Supraventricular tachycardia
- Wolff-Parkinson-White Pattern
 - Asymptomatic preexcitation in sinus rhythm
 - No symptoms
- Manifest pathway
 - Antegrade +/- retrograde conduction
- Concealed pathway
 - Retrograde conduction only

WPW electrophysiology






WPW electrophysiology








on during sinus




Ortodromic AV-reentrant tachycardia (AVRT)



Response to premature atrial stimuli



Antidromic AV-reentrant tachycardia (AVRT)




Mechanisms of pathway-mediated SVT

Ortodromic



Antidromic

Multiple pathways



The asymptomatic WPW pattern

Cardiac arrest in the WPW syndrome and atrial fibrillation



Incidence

Symptomatic pts: 0.3 – 0.9 % per patient year¹

Asymptomatic pts: 0.1 % per patient year²

1/14 pediatric patients with 70 years life expectancy

¹Munger TM et al, *Circulation* 1993

²Klein GJ et al, *Circulation* 1989


aV₁

V₁

1 s



PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern



* patients unable to perform an exercise stress test should undergo risk-stratification with an EP study

Δ prior to invasive testing, patients and the parents/guardians should be counseled to discuss the risks and benefits of proceeding with invasive studies, risks of observation only, and risks of medication strategy.

† patients participating at moderate-high level competitive sports should be counseled with regards to risk-benefit of ablation (Class II A) and follow the 36th Bethesda Conference Guidelines⁶

†† in the absence of inducible atrial fibrillation, the shortest pre-excited RR interval determined by rapid atrial pacing is a reasonable surrogate

Shortest preexcited RR evaluation



Acute treatment

Hemodynamically stable regular narrow QRS tachycardia

Table 1 Recommendations for acute treatment of haemodynamically stable regular narrow QRS tachycardia in infants and children

Drug/intervention	Dosage (iv)	Class	Level
Vagal manoeuvres	Ice immersion, gastric tube insertion in infants, Valsalva, and head stand in older children	I	B
Transoesophageal atrial overdrive pacing ^a		I	B
Adenosine → WPW – atrial fibrillation!	Rapid bolus starting dosages: For infants: 0.15 mg/kg. For > 1 year of age: 0.1 mg/kg Increasing dosage up to 0.3 mg/kg.	I	B
Verapamil ^{b,c} Contraindicated <1 year!!!	0.1 mg/kg slowly over 2 min	I	B
Flecainide ^b	1.5–2 mg/kg over 5 min	IIa	B
Propafenone ^b	Loading: 2 mg/kg over 2 h Maintenance: 4–7 µg/kg/min	IIa	B
Amiodarone	Loading: 5–10 mg/kg over 60 min. Maintenance infusion: 5–15 µg/kg/min	IIb	B

iv, intravenously; Class, recommendation class; Level, level of evidence.

^aMost effective if AV reentrant tachycardias or atrial flutter.

^bMyocardial depressant effect.

^cContraindicated in infants <1 year of age.

If unstable and critically ill – cardioversion!

Oral prophylactic treatment

Prophylactic antiarrhythmic drugs for SVT during the first 6–12 months of life¹
 Postpone ablation to >5 yrs²
 In-hospital initiation except beta-blockers and amiodarone

Table 3 Suggested oral antiarrhythmic drugs for SVT and VT in infants and children

Drug	Total daily dosage per body weight divided in × doses	Main contraindications and precautions	Features prompting lower dose or discontinuation	AV nodal slowing
Digoxine		→ Not for WPW syndrome!	Bradycardia	Moderate
Propranolol	1–3 mg/kg in 3× daily	Asthma bronchiale	Bradycardia	Moderate
Atenolol	0.3–1.3 mg/kg in 1× daily	Asthma bronchiale	Bradycardia	Moderate
Verapamil	4–8 mg/kg in 3× daily	Myocardial depressant effect Contraindicated <1 year!!!	Bradycardia	Marked
Flecainide	2–7 mg/kg in 2× daily	Contraindicated if creatinine clearance <50 mg/mL or E. Caution if conduction system disease.	QRS duration increase >25% above baseline	None
Propafenone	200–600 mg/m ² or 10–15 mg/kg in 3× daily	Contraindicated if reduced LVEF. Caution if conduction system disease and renal impairment.	QRS duration increase >25% above baseline	Slight
Sotalol	2–8 mg/kg in 2× daily	Contraindicated if significant LV hypertrophy, systolic HF, pre-existing QT prolongation, hypokalaemia, creatinine clearance <50 mg/mL and asthma bronchiale. Moderate renal dysfunction requires careful adaptation of dose	QT interval >500 ms	Similar to high-dose beta-blockers
Amiodarone	Loading: 10 mg/kg for 10 days. Maintenance: 5 mg/kg in 1× daily	Caution when using concomitant therapy with QT-prolonging drugs, HF. Dose of vitamin K antagonists and of digitoxin/digoxin should be reduced.	QT interval >500 ms	Slight

LVEF, left ventricular ejection fraction; HF, heart failure.

¹Lemler MS et al. AHJ 1997

²Friedman RA, PACE 2002

Brugada J et al. EHRA/AEPC consensus statement. Europace 2013

Catheter ablation

AVNRT

Chronic Therapy

Catheter ablation for slow pathway modification is recommended in symptomatic patients or in patients with an ICD.

243–247



AVRT

Chronic therapy

Catheter ablation of the accessory pathway is recommended in patients with symptomatic AVRT and/or pre-excited AF.^a

320–322



Catheter ablation of concealed accessory pathways may be considered in symptomatic patients with frequent episodes of AVRT

244–247



AFI

Chronic therapy

One-time or repeated cardioversion associated with AAD are recommended as a long-term alternative for patients with infrequent AFL recurrences or refusing ablation.

152,153



In patients with recurrent or poorly tolerated typical AFL, CTI ablation is recommended for preventing recurrences with a low incidence of complications.

153,154



In patients with depressed LV systolic function, ablation may be considered to revert dysfunction due to tachycardiomyopathy, and prevent recurrences.





155,156




Asymptomatická preexcitace

Table 17 Management of asymptomatic pre-excitation


Recommendation	Reference	
Electrophysiologic testing may be considered for risk stratification in subjects with asymptomatic ventricular pre-excitation.	322,339–345	
Catheter ablation of accessory pathways may be considered in asymptomatic patients with accessory pathways with antegrade refractory period <240 ms, inducible atrioventricular reentrant tachycardia triggering pre-excited atrial fibrillation, and multiple accessory pathways. ^a	322,343,345	
Observation without treatment may be reasonable in asymptomatic WPW patients who are considered to be at low risk following electrophysiology study or due to intermittent pre-excitation.	322,341	
Screening programmes may be considered for risk stratification of asymptomatic subjects with pre-excited ECG.	322,341	



6-HIS dis
8-HIS pro
10-CS 9.10
11-CS 7.8
12-CS 5.6
13-CS 3.4
14-CS 1.2
5-Abl bip
7-Abl uni
9-RVa




Atriofascicular connection (“Mahaim”)



- AV node and His bundle like structure
- Lateral tricuspid annulus
- Connected to distal right bundle
- Only antegrade conduction
- Decremental properties

Mahaim-mediated SVT



Nodo-/fasciculoventricular pathways

